Aurobindo Pharma Financial Statements

Aurobindo Pharma Profit & Loss Statement

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2021 Mar-2020 Mar-2018 Mar-2017
Growth matrix (%)        
Revenue growth 7.26 40.30 10.40 8.08
Op profit growth 9.64 29 9.83 7.72
EBIT growth 13.90 23.20 6.29 4.10
Net profit growth 88.40 16.80 5.28 13.70
Profitability ratios (%)        
OPM 21.50 21.10 22.90 23
EBIT margin 18.80 17.70 20.20 20.90
Net profit margin 21.50 12.30 14.70 15.40
RoCE 18.40 20.40 22 24.50
RoNW 6.88 4.97 5.76 6.91
RoA 5.26 3.54 4.01 4.51
Per share ratios ()        
EPS 91 48.50 41.40 38.90
Dividend per share 4 3 2.50 2.50
Cash EPS 73 31.80 31.80 32
Book value per share 374 287 199 160
Valuation ratios        
P/E 9.68 8.51 13.50 17.40
P/CEPS 12.10 13 17.50 21.10
P/B 2.36 1.44 2.80 4.22
EV/EBIDTA 9.01 5.38 9.33 11.90
Payout (%)        
Dividend payout -- -- 6.04 5.97
Tax payout (44) (24) (25) (25)
Liquidity ratios        
Debtor days 57.60 58.40 64.80 90.20
Inventory days 123 107 113 103
Creditor days (56) (53) (71) (79)
Leverage ratios        
Interest coverage (63) (13) (43) (47)
Net debt / equity -- 0.18 0.30 0.30
Net debt / op. profit -- 0.61 0.93 0.83
Cost breakup ()        
Material costs (40) (42) (41) (43)
Employee costs (14) (14) (13) (12)
Other costs (24) (23) (23) (22)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2021 Mar-2020 Mar-2018 Mar-2017
Revenue 24,775 23,099 16,463 14,910
yoy growth (%) 7.26 40.30 10.40 8.08
Raw materials (9,902) (9,735) (6,753) (6,434)
As % of sales 40 42.10 41 43.20
Employee costs (3,535) (3,219) (2,131) (1,768)
As % of sales 14.30 13.90 12.90 11.90
Other costs (6,004) (5,280) (3,808) (3,273)
As % of sales 24.20 22.90 23.10 22
Operating profit 5,333 4,864 3,772 3,434
OPM 21.50 21.10 22.90 23
Depreciation (1,055) (967) (558) (428)
Interest expense (74) (305) (78) (67)
Other income 381 192 105 116
Profit before tax 4,584 3,784 3,241 3,056
Taxes (2,010) (914) (818) (760)
Tax rate (44) (24) (25) (25)
Minorities and other 1.02 1.45 0.26 0.47
Adj. profit 2,576 2,872 2,423 2,297
Exceptional items 2,815 (26) -- --
Net profit 5,335 2,831 2,423 2,302
yoy growth (%) 88.40 16.80 5.28 13.70
NPM 21.50 12.30 14.70 15.40
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2018 Mar-2017
Profit before tax 4,584 3,784 3,241 3,056
Depreciation (1,055) (967) (558) (428)
Tax paid (2,010) (914) (818) (760)
Working capital 11,358 8,128 4,838 1,882
Other operating items -- -- -- --
Operating cashflow 12,877 10,032 6,703 3,751
Capital expenditure 10,750 9,355 4,131 1,453
Free cash flow 23,627 19,387 10,834 5,203
Equity raised 18,982 16,275 11,951 10,876
Investments 552 516 289 226
Debt financing/disposal 5,437 5,651 3,330 1,920
Dividends paid -- -- 146 114
Other items -- -- -- --
Net in cash 48,597 41,830 26,551 18,340
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2019 Mar-2018
Equity capital 58.60 58.60 58.60 58.60
Preference capital -- -- -- --
Reserves 21,871 16,766 13,832 11,622
Net worth 21,930 16,825 13,891 11,680
Minority interest
Debt 5,291 5,826 6,967 4,770
Deferred tax liabilities (net) 575 292 281 616
Total liabilities 27,795 22,943 21,140 17,068
Fixed assets 12,435 11,382 10,143 8,104
Intangible assets
Investments 591 555 360 312
Deferred tax asset (net) 453 163 183 539
Net working capital 8,842 8,000 8,496 6,851
Inventories 9,027 7,700 7,246 5,858
Inventory Days 133 122 -- 130
Sundry debtors 3,503 4,315 3,414 3,080
Debtor days 51.60 68.20 -- 68.30
Other current assets 2,371 1,970 3,151 2,326
Sundry creditors (3,213) (2,745) (2,744) (2,590)
Creditor days 47.30 43.40 -- 57.40
Other current liabilities (2,846) (3,240) (2,570) (1,824)
Cash 5,474 2,842 1,957 1,262
Total assets 27,795 22,943 21,140 17,068
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Sep-2021 Jun-2021 Mar-2021 Dec-2020 Sep-2020
Gross Sales 5,890 5,692 5,992 6,353 6,378
Excise Duty -- -- -- -- --
Net Sales 5,890 5,692 5,992 6,353 6,378
Other Operating Income 52 10.10 9.82 11.80 106
Other Income 96.60 110 78.80 2,947 53.80
Total Income 6,039 5,812 6,080 9,312 6,537
Total Expenditure ** 4,766 4,502 4,735 5,011 5,071
PBIDT 1,272 1,310 1,345 4,301 1,466
Interest 10.40 12.90 18.20 19.50 15.70
PBDT 1,262 1,297 1,327 4,282 1,450
Depreciation 294 280 266 277 257
Minority Interest Before NP -- -- -- -- --
Tax 192 223 446 1,083 424
Deferred Tax 78.80 25.20 (186) (24) (38)
Reported Profit After Tax 697 770 801 2,946 807
Minority Interest After NP (0.30) -- (0.40) (0.10) (0.60)
Net Profit after Minority Interest 697 770 802 2,946 808
Extra-ordinary Items -- -- 0.40 2,053 --
Adjusted Profit After Extra-ordinary item 697 770 801 894 808
EPS (Unit Curr.) 11.90 13.10 13.70 50.30 13.80
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) 150 150 -- 150 125
Equity 58.60 58.60 58.60 58.60 58.60
Public Shareholding (Number) -- -- -- -- --
Public Shareholding (%) -- -- -- -- --
Pledged/Encumbered - No. of Shares -- -- -- -- --
Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- --
Pledged/Encumbered - % in Total Equity -- -- -- -- --
Non Encumbered - No. of Shares -- -- -- -- --
Non Encumbered - % in Total Promoters Holding -- -- -- -- --
Non Encumbered - % in Total Equity -- -- -- -- --
PBIDTM(%) 21.60 23 22.40 67.70 23
PBDTM(%) 21.40 22.80 22.10 67.40 22.70
PATM(%) 11.80 13.50 13.40 46.40 12.70
Open ZERO Brokerage Demat Account
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity